The effect estimates by IVW method suggested the protective role of increased iron status on prostate cancer, with ORs of 0.91 (95% CI: 0.84, 0.99; P = 0.035), 0.81 (95% CI: 0.65, 1.00; P = 0.046), 0.94 (95% CI: 0.88, 0.99; P = 0.029), and 1.15 (95% CI: 0.98, 1.35; P = 0.084) for genetically predicted increased serum iron, log-transformed ferritin, transferrin saturation, and transferrin (Table 1). This evidence concerns the gene TF and prostate carcinoma.